Abstract:Abstract Background One of the major challenges in currently chemotherapeutic theme is lacking effective biomarkers for drug response and sensitivity. Our current study focus on two promising biomarkers, ERCC1 (excision repair cross-complementing group 1) and BRCA1 (breast cancer susceptibility gene 1). To investigate their potential role in serving as biomarkers for drug sensitivity in cancer patients with metastases, we statistically measure the mRNA expression level of ERCC1 and BRCA1 in tumor cells isolated from malignant effusions and correlate them with cisplatin and/or docetaxel chemosensitivity. Methods Real-time quantitative PCR is used to analysis related genes expression in forty-six malignant effusions prospectively collected from non-small cell lung cancer (NSCLC), gastric and gynecology cancer patients. Viable tumor cells obtained from malignant effusions are tested for their sensitivity to cisplatin and docetaxel using ATP-TCA assay. Results ERCC1 expression level is negatively correlated with the sensitivity to cisplatin in NSCLC patients (P = 0.001). In NSCLC and gastric group, BRCA1 expression level is negatively correlated with the sensitivity to cisplatin (NSCLC: P = 0.014; gastric: P = 0.002) while positively correlated with sensitivity to docetaxel (NSCLC: P = 0.008; gastric: P = 0.032). A significant interaction is found between ERCC1 and BRCA1 mRNA expressions on sensitivity to cisplatin (P = 0.010, n = 45). Conclusion Our results demonstrate that ERCC1 and BRCA1 mRNA expression levels are correlated with in vitro chemosensitivity to cisplatin and/or docetaxel in malignant effusions of NSCLC and gastric cancer patients. And combination of ERCC1 and BRCA1 may have a better role on predicting the sensitivity to cisplatin than the single one is considered.

Study on the relationship between expression levels of ERCC1 mRNA and sensitivity of tumor cells isolated from malignant effusions to cisplatin in vitro

Meta-analysis of excision repair cross-complementation group 1 (ERCC1) association with response to platinum- based chemotherapy in ovarian cancer.

ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel

Expression of ERCC-1 in NSCLC tissue and its value for appraising chemotherapy

Excision repair cross complementing-1 gene expression in small cell lung cancer and chemo-sensitivity to cisplatin/etoposide regimen

A Meta-Analysis Identifies ERCC1 Gene Polymorphism As a Predictor of Better Patient Response to Treatment with Radiochemotherapy

High Expression of ERCC1 is a Poor Prognostic Factor in Chinese Patients with Non-Small Cell Lung Cancer Receiving Cisplatin-Based Therapy

Prognostic Significance of ERCC1 Mrna Expression in Patients with Non-Small Cell Lung Cancer Receiving Platinum-Based Chemotherapy

[Relationship between BRCA1 mRNA expression in tumor cells from malignant effusions and chemosensitivity to cisplatin in patients with metastatic malignant effusions].

Expression of ERCC1 and BRCA1 Predict the Clinical Outcome of Non-Small Cell Lung Cancer in Patients Receiving Platinum-Based Chemotherapy.

Relationship Between Expression of ERCC1 and Effect of Platinum-based Chemotherapy in Patients with Advanced NSCLC

Protein Expression Levels Of Excision Repair Cross-Complementation Group 1 And Xeroderma Pigmentosum D Correlate With Response To Platinum-Based Chemotherapy In The Patients With Advanced Epithelial Ovarian Cancer

Positive Expression of ERCC1 Predicts a Poorer Platinum-Based Treatment Outcome in Chinese Patients with Advanced Non-Small-cell Lung Cancer

First-line Gemcitabine Plus Cisplatin in Nonsmall Cell Lung Cancer Patients.

Detection of Cell-Free ERCC1 and Thymidylate Synthase (TS) Mrna in Malignant Effusions and Its Association with Anticancer Drug Sensitivity.

Expression of excision repair cross-complementation group 1 in non-small-cell lung cancer and its contribution to Cisplatin-based adjuvant chemotherapy

Meta-Analysis of Predictive Value of ERCC1 Protein Expression in Non-Small Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy

Effect of RRM1 and BRCA1 Expressions on Efficiency of Gemcitabine and Platinum in Patients with Advanced Non-Small Cell Lung Cancer

Enhanced Cisplatin Cytotoxicity by RNA Interfering the Excision Repair Cross-complementing Gene 1 in Lung Cancer Cell A549/DDP

ERCC1 and BRCA1 Expressions in the Tissues of Colorectal Cancer and Its Relationship with Clinical Significance of Platinum-Based Chemotherapy

Relationship Between Plasma BRCA1 Mrna Expression and Sensitivity to Docetaxel and Cisplatin in Gastric Cancer.